Clinical Trials List
2024-12-02 - 2030-12-09
Phase II
Recruiting2
ICD-10M32.0
Drug-induced systemic lupus erythematosus
ICD-10M32.10
Systemic lupus erythematosus, organ or system involvement unspecified
ICD-10M32.11
Endocarditis in systemic lupus erythematosus
ICD-10M32.12
Pericarditis in systemic lupus erythematosus
ICD-10M32.13
Lung involvement in systemic lupus erythematosus
ICD-10M32.14
Glomerular disease in systemic lupus erythematosus
ICD-10M32.15
Tubulo-interstitial nephropathy in systemic lupus erythematosus
ICD-10M32.19
Other organ or system involvement in systemic lupus erythematosus
ICD-10M32.8
Other forms of systemic lupus erythematosus
ICD-10M32.9
Systemic lupus erythematosus, unspecified
ICD-9710.0
Systemic lupus erythematosus
-
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/12
Investigators and Locations
Co-Principal Investigator
- 高宗楙 Division of Rheumatology
- HSIN-HUA CHEN Division of Rheumatology
- 謝佳偉 Division of Rheumatology
- Huey-En Tzeng
- 許鶴忀 Division of Rheumatology
- 陳彥如 Division of Rheumatology
- 顏在弘 Division of Rheumatology
- Kuan-Der Lee
- Yi-Hsing Chen 無
- 賴國隆 Division of Rheumatology
- 洪維廷 Division of Rheumatology
- Yi-Ming Chen Division of Rheumatology
- 廖育婉 Division of Rheumatology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
6 participants
-
Global
179 participants
